Do whole-blood omega-3 measures reflect membrane EPA and DHA status and reveal a selective EPA gap?

Clinical and methodological evidence

• Robust biomarker correlation: Whole-blood and dried blood spot (DBS) omega-3 measurements are highly validated surrogates for cellular membrane incorporation. Venous whole-blood EPA and DHA levels explain approximately 79% to 84% of the variance observed in erythrocyte (RBC) membranes ($R^2 \approx 0.79\text{--}0.84$).
• High agreement with gold standard: Dried blood spot finger-stick sampling correlates almost perfectly with the RBC Omega-3 Index ($r \approx 0.96\text{--}0.98$), allowing clinical laboratories to reliably estimate a patient's membrane status from a simple capillary sample.
• Temporal characteristics: Because whole blood integrates both the stable RBC fraction (reflecting a 90-to-120-day lifespan) and the dynamic plasma fraction, it serves as a highly reliable marker of tissue status, correlating far better than plasma total fatty acids alone ($r \approx 0.50$).

Mechanistic explanations

• Myocardial tissue surrogate: Erythrocyte membrane EPA and DHA levels (the Omega-3 Index) correlate strongly with myocardial tissue omega-3 levels, establishing RBC membrane incorporation as a validated proxy for cardiac tissue status.
• Asymmetrical metabolic pathways: The retroconversion of DHA back into EPA via peroxisomal $\beta$-oxidation is highly constrained, accounting for less than 1.5% to 10% of plasma DHA in human tracer studies. Consequently, the body cannot readily synthesize EPA from existing DHA pools.
• Distinct tissue retention: The human body preferentially retains DHA in target structures (such as neural and retinal tissues) while rapidly metabolizing or clearing EPA. This asymmetric retention and low retroconversion rate explain why a low total omega-3 pool can co-exist with normal DHA levels, creating a selective EPA gap.

Bottom line

Whole-blood omega-3 measurements reliably mirror cell membrane incorporation. A discordant profile of low total omega-3 alongside normal DHA indicates a selective EPA gap rather than a global deficiency, a phenomenon driven by the body's preferential retention of DHA and its inability to efficiently retroconvert DHA back into EPA.